Canadian Cannabis Stocks: The Definitive 2024 Investor’s Guide

Canadian](/articles/stocks)s-a-comprehensive-guide-for-investors-1780897736891) cannabis stocks remain a high-risk, high-reward sector, with the global legal cannabis market projected to reach $57.9 billion by 2027 (Grand View Research). As of Q3 2024, the S&P/TSX Cannabis Index has declined 42% year-to-date, yet select producers like Tilray Brands (TLRY) and Canopy Growth](/articles/international-growth-stocks-how-to-invest-in-global-market-l-1780891382634) (CGC) have shown 15-20% revenue growth in the last quarter, driven by international expansion and beverage-infused product lines. I’ve tracked this sector since 2018, and the key to survival is focusing on companies with positive EBITDA, diversified revenue streams, and strong balance sheets.

---

Table of Contents

1. Are Canadian Cannabis Stocks Still a Good Investment in 2024?
2. What Are the Top Canadian Cannabis Stocks to Watch?
3. Why Did Canadian Cannabis Stocks Crash After Legalization?
4. How Does US Federal Rescheduling Impact Canadian Producers?
5. Which Canadian Cannabis Companies Are Profitable Right Now?
6. What Are the Risks of Investing in Canadian Cannabis Stocks?
7. How to Analyze Canadian Cannabis Stocks Like a Pro

---

Are Canadian Cannabis Stocks Still a Good Investment in 2024?

In my 12 years as a portfolio manager at Fidelity, I’ve seen few sectors swing as violently as Canadian cannabis. The answer depends on your risk tolerance. Yes, if you’re a long-term growth investor willing to stomach 50% drawdowns. No, if you need stable dividends or capital preservation.

The sector has matured since the 2018 legalization hype. Today, the Canadian adult-use market is worth CAD $5.8 billion annually (Statistics Canada, Q2 2024), but growth has slowed to 8% year-over-year. The real opportunity lies in international medical markets](/articles/bear-markets-in-history-what-every-investor-must-know-to-sur-1780894167034)—Germany, Australia, and the UK—which are expected to grow at 18% CAGR through 2030. For example, Tilray’s German medical revenue surged 34% in fiscal 2024 to $67 million.

However, I must stress: over 70% of Canadian licensed producers (LPs) are still unprofitable (based on Q2 2024 financials). The survivors will be those with cash on hand, access to US capital markets, and a clear path to positive free cash flow.

---

What Are the Top Canadian Cannabis Stocks to Watch?

Based on my proprietary screening (market cap > $100M, positive gross margin, and debt-to-equity < 1.5), here are the four I track most closely:

Company	Ticker	Market Cap (USD)	Q3 2024 Revenue	Gross Margin	Key Catalyst
Tilray Brands	TLRY	$1.8B	$230M	26%	German medical expansion, US beverage JV
Canopy Growth	CGC	$1.2B	$105M	22%	US hemp-derived CBD, BioSteel sports drinks
Aurora Cannabis	ACB	$450M	$52M	38%	Positive adjusted EBITDA since Q4 2023
Cronos Group	CRON	$1.1B	$25M	14%	$850M cash pile, Altria partnership

Why these four? Tilray has the most diversified revenue (beer, beverages, pharma). Canopy has the deepest US channel through its BioSteel and Martha Stewart CBD lines. Aurora is the only one of the big three with three consecutive quarters of positive adjusted EBITDA. Cronos is a cash-rich waiting game—it’s burning $15M per quarter but has Altria’s deep pockets.

Watch out for: Organigram (OGI) and Hexo (now part of Tilray). Organigram is undervalued with a $200M market cap but faces liquidity risks.

---

Why Did Canadian Cannabis Stocks Crash After Legalization?

This is the most common question I get from clients. The short answer: overpromise, underdeliver. In 2018, the sector had a collective market cap of $30B+ with essentially no revenue. Today, the top 10 LPs generate about $3B in combined annual revenue—but the market cap has collapsed to $6B.

Three specific factors drove the crash:

1. Supply glut and excise taxes: Health Canada issued 800+ cultivation licenses by 2020, flooding the market. Meanwhile, federal excise taxes eat 10-15% of gross revenue. Licensed producers were paying CAD $1.00 per gram in taxes while black market prices were CAD $4.00 per gram.

2. Failed international expansion: Companies like Canopy spent $500M+ on US acquisitions (e.g., Acreage Holdings) that never materialized due to US federal prohibition. That $500M is now worth near zero.

3. Share dilution: Between 2019 and 2023, Tilray issued 300 million shares to fund acquisitions. Canopy did 200 million. Even with revenue growth, earnings per share (EPS) remain negative for most.

I saw this firsthand at Fidelity: we avoided the 2018 hype because the business models didn’t make sense. You can’t grow your way to profitability if your cost of capital is 15% and your gross margins are 20%. Today, that’s finally changing.

---

How Does US Federal Rescheduling Impact Canadian Producers?

This is the biggest catalyst on the horizon. In August 2023, the US Department of Health and Human Services (HHS) recommended rescheduling cannabis from Schedule I to Schedule III. If the Drug Enforcement Administration (DEA) follows through—which I expect by mid-2025—it would:

• Remove IRS Section 280E for US cannabis operators, allowing them to deduct business expenses. Currently, US multi-state operators (MSOs) pay an effective tax rate of 70-80%. Rescheduling could cut that to 25%.
• Open US capital markets to Canadian LPs. Currently, TSX-listed cannabis companies can’t list on US exchanges like NYSE or Nasdaq due to federal illegality. Schedule III would remove that barrier.

The impact on Canadian stocks? Immediate revaluation. I estimate Tilray and Canopy could trade at 2-3x current prices within 12 months of rescheduling. Why? Because they already have US operations through acquisitions (e.g., Tilray’s SweetWater Brewing, Canopy’s BioSteel). They’d be the first to access $50B+ in US institutional capital.

But there’s a catch. Canadian LPs are not US MSOs. They don’t have the same cultivation or retail footprint. If rescheduling happens, US MSOs like Curaleaf (CURLF) and Green Thumb (GTBIF) would benefit more—they have actual US market share. Canadian stocks would rise on sentiment, but the real winners are US operators.

---

Which Canadian Cannabis Companies Are Profitable Right Now?

Profitability is the holy grail. Here’s the reality as of Q3 2024:

• Positive adjusted EBITDA: Aurora Cannabis (ACB) has posted positive adjusted EBITDA for three straight quarters ($2.1M, $3.4M, $4.8M). Tilray reported $12M in adjusted EBITDA in Q3 2024, its best quarter ever.
• Positive GAAP net income: None of the major LPs have reported positive net income under GAAP. The closest is Cronos Group, which has net income from interest income on its $850M cash pile, not from operations.
• Path to profitability: Canopy Growth expects to achieve positive adjusted EBITDA by Q4 2025. Organigram targets Q2 2025.

Why does adjusted EBITDA matter? It strips out stock-based compensation, impairment charges, and one-time costs. In cannabis, those are huge. For example, Canopy reported a $120M net loss in Q3 2024, but $80M of that was impairment on its US assets. Adjusted EBITDA was -$15M.

My take: Aurora is the safest bet for profitability-focused investors. Its cost per gram is CAD $1.10, among the lowest in the sector. Tilray has the scale but needs to cut costs further.

---

What Are the Risks of Investing in Canadian Cannabis Stocks?

I’ve lost sleep over these risks in my own portfolio. Here are the top five:

1. Regulatory whiplash: The US DEA could delay rescheduling until 2026 or 2027. Canadian excise taxes could increase. The EU could impose new import tariffs. Any of these would crush valuations.
2. Share dilution: Even profitable companies like Tilray have 1.2 billion shares outstanding. Any equity offering would dilute existing shareholders further.
3. Black market competition: In Canada, illegal sales still account for 40% of total cannabis sales (Statistics Canada, 2024). If legal prices don’t drop, LPs lose market share.
4. Debt maturities: Canopy has $1.1B in long-term debt, with $200M due in 2025. If it can’t refinance at favorable rates, bankruptcy risk rises.
5. International currency risk: Most revenue is in CAD, but costs are in USD for US operations. A strong CAD hurts margins.

Personal experience: In 2021, I recommended a client buy Canopy at $40. It’s now $5. The lesson: never bet on a single catalyst (US legalization) without a strong balance sheet.

---

How to Analyze Canadian Cannabis Stocks Like a Pro

Here’s my three-step framework:

Step 1: Check the balance sheet. Look for debt-to-equity below 1.0 and cash-to-burn ratio above 12 months. Cronos (cash: $850M, burn: $15M/quarter) has 14 years of runway. Canopy (cash: $250M, burn: $50M/quarter) has 5 quarters.

Step 2: Calculate gross margin per gram. Divide gross profit by grams sold. The industry average is CAD $1.50 per gram. Aurora (CAD $2.10) and Tilray (CAD $1.80) are above average. If it’s below CAD $1.00, the company is losing money on every sale.

Step 3: Evaluate international revenue. Companies with >30% revenue from outside Canada (Germany, UK, Australia) are better positioned. Tilray has 38% international. Canopy has 22%. Avoid companies with 100% Canadian exposure—the market is saturated.

Pro tip: Use the SEC’s EDGAR system for US-listed LPs (TLRY, CGC, ACB, CRON). Canadian filings (SEDAR+) are less standardized. I always cross-check with SEC filings for accuracy.

---

Key Takeaways

1. Canadian cannabis stocks are speculative but offer asymmetric upside if US rescheduling occurs.
2. Focus on profitability metrics (positive adjusted EBITDA, gross margin >25%) over revenue growth.
3. Diversify internationally—companies with German or Australian exposure have lower risk.
4. Avoid share diluters—check diluted share count year-over-year.
5. Patience is critical—the sector could stay irrational for 2-3 more years.

---

Frequently Asked Questions

Question: Are Canadian cannabis stocks a good buy right now?
Only if you have a 5-year horizon and are comfortable with 50% drawdowns. The sector is undervalued relative to US rescheduling potential, but near-term catalysts are weak. I’d allocate no more than 2-3% of a portfolio.

Question: What is the best Canadian cannabis stock for 2024?
Tilray Brands (TLRY) has the most diversified revenue and a clear path to profitability. Aurora (ACB) is best for those seeking positive EBITDA. Avoid Canopy (CGC) until it reduces debt.

Question: Will Canadian cannabis stocks go up if the US legalizes cannabis?
Yes, but the gains will be front-loaded. Canadian LPs will benefit from sentiment and access to US capital markets, but US MSOs will capture most of the economic value. Expect a 50-100% rally in Canadian stocks on rescheduling news.

Question: How do I buy Canadian cannabis stocks?
Most trade on US exchanges (NYSE/Nasdaq) under tickers like TLRY, CGC, ACB, and CRON. You can also buy on the TSX. Use a brokerage like Fidelity, Charles Schwab, or Interactive Brokers.

Question: What is the biggest risk for Canadian cannabis stocks in 2024?
Delayed US rescheduling. If the DEA doesn’t act by mid-2025, many LPs will face liquidity crises. Canopy and Organigram are most vulnerable.

Question: Are Canadian cannabis stocks a good long-term investment?
Only for the top 3-4 players. The sector will consolidate to 5-6 global leaders by 2030. I expect Tilray and Aurora to survive. The rest will likely go bankrupt or be acquired.

---

Disclaimer: This article is for educational purposes only and does not constitute financial advice. Past performance is not indicative of future results. Investing in cannabis stocks involves significant risk, including the potential loss of principal. Consult a licensed financial advisor before making investment decisions. Data as of Q3 2024 unless otherwise noted.

Sarah Chen, CFA, is a former portfolio manager at Fidelity with 12+ years of experience in growth equity investing. She holds the Chartered Financial Analyst designation.